Head-to-head: docetaxel challenges paclitaxel

European Journal of Cancer, Supplement

Volumn 4, Issue 4, 2006, Pages 4-8

  Jones, Stephen ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Docetaxel; Metastatic; Monotherapy; Taxoid; Toxicity management

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MITOMYCIN; PACLITAXEL; PROTEIN BCL 2; TAXOID; TRASTUZUMAB; VINBLASTINE;

ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; CYTOTOXICITY; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; TAXUS BREVIFOLIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR CELL;

EID: 33646174250     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(06)80002-9     Document Type: Article

References (25)

1. Gligorov J., and Lotz J. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 Suppl 2 (2004) 3-8
2. Riou J., Naudin A., and Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187 1 (1992) 164-170
3. Abstr. 2292. Riou J.P., and Combeau C. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 35 385 (1994)
4. (2 Suppl 4). Lavelle F., Bissery M., Combeau C., Riou J., Vrignaud P., and Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22 (1995) 3-16
5. Hanauske A., Depenbrock H., Shirvani D., and Rastetter J. Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of humanbreast cancer cell lines in vitro. Eur J Cancer 30A 11 (1994) 1688-1694
6. Hanauske A., Degen D., Hilsenbeck S., Bissery M., and Von Hoff D. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3 2 (1992) 121-124
7. Pegram M., Konecny G., O'Callaghan C., Beryt M., Pietras R., and Slamon D. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96 10 (2004) 739-749
8. Fujimoto-Ouchi K., Tanaka Y., and Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 7 4 (2001) 1079-1086
9. Valero V., Jones S., Von Hoff D., et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16 10 (1998) 3362-3368
10. Jones S., Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 24 (2005) 5542-5551
11. Seidman A., Hudis C., Albanel J., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16 10 (1998) 3353-3361
12. Wist E., Sommer H., Ostenstad B., Risberg T., and Fjaestad K. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 43 1 (2004) 11-14
13. Perez E., Vogel C., Irwin D., Kirshner J., and Patel R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 73 1 (2002) 85-88
14. ten Tije A., Smorenburg C., Seynaeve C., et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 40 3 (2004) 352-357
15. Lombardi D., Crivellari D., Scuderi C., et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori 90 3 (2004) 285-288
16. Perez E., Vogel C., Irwin D., Kirshner J., and Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19 22 (2001) 4216-4223
17. Seidman AD, Cirrincione C, Harris L, et al. CALGB 9840: Phase IIIstudy of weekly (W) paclitaxed (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. In: Proc ASCO 2004, 22, Abstr. 512.
18. Sparano JA, Martino S, Jones V, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. In: SABCS 2005. Abstr. 48.
19. 2 as second line chemotherapy in advanced breast cancer. Breast Cancer Res Treat 76 S88 Suppl 1 (2002)
20. Vogel C., Wojtukiewicz M., Carroll R., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind,placebo-controlled phase III study. J Clin Oncol 23 6 (2005) 1178-1184
21. Downloaded. National Comprehensive Cancer Network (NCCN) guidelines for prophylaxis with myeloid growth factors (2005). http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf
22. Nabholtz J., Senn H., Bezwoda W., et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17 5 (1999) 1413-1424
23. Bontenbal M., Creemers G., Braun H., et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patientswith metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23 28 (2005) 7081-7088
24. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 12 (2002) 2812-2823
25. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 19 (2005) 4265-4274